Asia Biomaterials (Wuhan) Co., Ltd.

Asia Biomaterials (Wuhan) Co., Ltd. (hereinafter referred to as “ABM”) is a high-tech enterprise integrating R&D, production and sales of high-value implantable medical devices for tissue regeneration and repair, mainly involving orthopedic biomaterials and wound regeneration materials. ABM has been recognized as a core medical device enterprise in China Optics Valley Bio-city, a Hubei Specialized, Refined, Unique & Innovative Enterprise, a Hubei Golden Seed Enterprise, and a Wuhan Gazelle Enterprise. It has four holding companies, three independent business divisions, and one overseas subsidiary, among which two are national high-tech enterprises.

ABM has a world-class 10,000-level clean production workshop complying with GMP standards. The total area of its headquarter base, new product production base and intelligent manufacturing base reaches approximately 23,000 square meters, including one "International Joint Laboratory for high-value Biomaterials and Devices" and four provincial/ministerial-level R&D platforms - Hubei Research Institute of Bioactive Materials and Devices, Hubei Engineering Research Center for Oral and Maxillofacial Medical Devices and Equipment, Hubei Provincial Technology Center for SMEs and Wuhan Enterprise R&D Center. ABM has Asia’s largest calcium-phosphorus bioactive material production base and has established multiple overseas cooperative R&D centers in the United States, Australia, South Korea and Belt and Road countries. It has successively led and undertaken numerous national-level projects, including the Project of National Key R&D Program, the Strategic Innovation Project of Open Bidding Mechanism led by the Ministry of Industry and Information Technology (MIIT) and the National Medical Products Administration (NMPA), the Project of National High-tech Development Program (863 Program), the Project of National Science and Technology Support Program, and the Project of Ministry of Science and Technology Inter-Governmental International Cooperation Program, representing national standards for technological innovation and transformation in the field of high-value biomaterials and devices.

ABM engages in the R&D, production and sales for more than 20 kinds of products, including orthopedic biomaterials series (DeepActiveTM, DeepActive Anti-TumorTM, DeepActive RegboneTM), wound regeneration materials series (DeepActive SkinTM), and oral repair biomaterials series. ABM’s products have currently obtained 15 medical device registration certificates issued by the NMPA, US FDA and EAEU countries, including 3 world-first innovative products, 5 strategic products enlisted in the National Key R&D Program, 2 innovative products selected as Breakthrough Products in the Grand Health Industry of Hubei Province, and 3 "Three-New" (New Brand, New Standard, New Achievement) products recognized at the World Health Expo.

ABM has established a top-tier international R&D teams. The core members have the background of studying and working in famous universities, research institutes and renowned enterprises at home and abroad. The team includes: 1 Chair of the Asia-Pacific Section of TERMIS and Vice President of the Chinese Society for Biomaterials, 1 Fellow of the Royal Society of New Zealand, 1 Academician of the Chinese Academy of Sciences, 1 Academician of the National Academy of Engineering (USA), 3 IUSBSE Fellows, 1 Chief Scientist of National Key R&D Program, 1 Young Top-notch Talent under the National Ten-Thousand Talents Program of the Central Organization Department, 2 Awardees of the Young Talent Support Project of the China Association for Science and Technology, 4 Recipients of Wuhan 3551 Talent Program, as well as numerous postdoctoral, PhD and master’s degree researchers.

ABM has been committed to continuously providing more efficient and affordable products, with emphasis on the philosophy of “International Standards, Excellent Quality, World-known Brand” , evolving into a vital strategic pillar driving technological innovation and high-quality development in the biomaterials industry.